title: Effects of cyclosporine and tacrolimus on maintenance therapy after renal transplantation.
abstract: The immunosuppressive agents cyclosporine A and tacrolimus have demonstrated efficacy in preventing acute organ rejection after renal transplantation, but no comparative studies of these 2 agents have been published. This study compared the effects of tacrolimus and cyclosporine A on the renal function, blood pressure, and serum glucose and lipid levels of patients who underwent cyclosporine A therapy and C2 monitoring or tacrolimus therapy and standard monitoring during the first 24 months after transplantation. By the end of the follow-up period, no significant difference between either treatment group was noted in the measures of creatine clearance; BUN, glucose, uric acid, and lipid levels; or diastolic blood pressure (P>.05 for all), which were maintained at normal values throughout the study. Systolic blood pressure was significantly lower in the cyclosporine A group at the end of the 1 st month (P<.025) but this difference was not evident at months 6, 12, and 24 (P>.05). These results indicate that tacrolimus and cyclosporine (when combined with C2 monitoring) were equally effective and safe in preventing acute organ rejection.
authors.affiliation: Cukurova University, Faculty of Medicine, Adana, Turkey.
authors.forename: Mustafa
authors.initials: M
authors.lastname: Balal
authors.forename: Saime
authors.initials: S
authors.lastname: Paydas
authors.forename: Yasar
authors.initials: Y
authors.lastname: Sertdemir
authors.forename: Ibrahim
authors.initials: I
authors.lastname: Karayaylali
authors.forename: Neslihan
authors.initials: N
authors.lastname: Seyrek
mesh_terms: D000328:Adult; D015331:Cohort Studies; D016572:Cyclosporine / Q000627:therapeutic use*; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D005260:Female; D006084:Graft Rejection; D006085:Graft Survival; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D016030:Kidney Transplantation / Q000276:immunology*; D008134:Long-Term Care; D008297:Male; D008875:Middle Aged; D011336:Probability; D011379:Prognosis; D012189:Retrospective Studies; D018570:Risk Assessment; D016559:Tacrolimus / Q000627:therapeutic use*; D014181:Transplantation Immunology / Q000187:drug effects* / Q000502:physiology; D016896:Treatment Outcome
chemical_list: D007166:Immunosuppressive Agents; D016572:Cyclosporine; D016559:Tacrolimus